Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

15.72 +0.33 (+2.14%)
Streaming Delayed Price Updated: 2:21 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 450,518
Open 15.69
Bid (Size) 15.68 (400)
Ask (Size) 15.72 (400)
Prev. Close 15.39
Today's Range 15.41 - 16.34
52wk Range 5.970 - 16.93
Shares Outstanding 42,052,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+114.8%
+114.8%
1 Month
+51.4%
+51.4%
3 Month
+80.5%
+80.5%
6 Month
+62.4%
+62.4%
1 Year
+133.2%
+133.2%

More News

Read More
News headline image
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress ↗
Via Chartmill
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy ↗
Via MarketBeat
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Meetings
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Provides Company Update and Anticipated Development Milestones for 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 15.72
When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 08/25/26 02:21 PM ET
What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 661.07M
How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
4D Molecular Therapeutics, Inc. - Common Stock has 661M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.